Application of ligustilide cyclopropanelactam in preparation of medicine for preventing and treating hyperuricemia nephropathy and renal injury and renal fibrosis caused by hyperuricemia

By reducing uric acid levels and inhibiting inflammation and fibrosis, cypropanol has solved the adverse reactions of existing hyperuricemia treatment drugs, and has significantly improved the clinical application prospects of hyperuricemia nephropathy and renal fibrosis.

CN119055637APending Publication Date: 2024-12-03HARBIN MEDICAL UNIVERSITY
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411122249.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing hyperuricemia treatment drugs have adverse reactions and toxic side effects, making it difficult to effectively prevent and treat hyperuricemia nephropathy and renal fibrosis.

Method used

Using cypropanolactam as the main active ingredient, the mouse hyperuricemia nephropathy model was constructed to detect its effects on uric acid level, renal function, inflammatory response and fibrosis degree, which proved that it can reduce uric acid level and improve the kidneys. Function, inhibition of inflammation and fibrosis.

Benefits of technology

Cyperpropanolactam significantly reduces the uric acid level in hyperuricemia mice, improves renal function, inhibits inflammation and fibrosis, has low toxic side effects, is safe, and has obvious prevention and treatment of hyperuricemia nephropathy and kidneys. The effect of fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055637A_ABST
    Figure CN119055637A_ABST
Patent Text Reader

Abstract

The invention provides application of ligustilide cyclopropanectam in preparation of a medicine for preventing and treating hyperuricemia nephropathy and renal injury and renal fibrosis caused by hyperuricemia, and relates to the technical field of medicines. The ligustilide as a natural medicinal plant source material has low toxicity and side effects and multi-target action performance, and has a good clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to an application of ligustifolia cyclopropane lactam in the preparation of a drug for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia. Background Art

[0002] Hyperuricemia is an inflammatory disease characterized by long-term purine metabolism disorders and persistently elevated blood uric acid levels. Hyperuricemia has become the fourth most common disease after diabetes, hypertension, and hyperlipidemia. According to a long-term follow-up cohort study, there is a significant association between uric acid levels and the risk of kidney disease. Specifically, every time the serum uric acid level increases by 1 mg / dL, the risk of kidney disease will increase by 7%-11%. Therefore, hyperuricemia has risen to a public health challenge that poses a major threat to human health and has put significant pressure on social medical resources.

[0003] In the clinical treatment of hyperuricemia, three main types of drugs are used: (1) drugs that inhibit uric acid production, such as xanthine oxidase inhibitors such as allopurinol and febuxostat. (2) drugs that promote uric acid excretion, such as benzbromarone and probenecid. (3) recombinant uricase drugs (such as purinesilver and rasburicase). However, currently used clinical drugs such as allopurinol and febuxostat may cause adverse reactions including renal damage and acute liver damage, and should be used with caution. Benzbromarone also has relatively serious liver toxicity, and uricase is a protein that can be misrecognized by the immune system and cause allergic reactions. These adverse reactions and various toxic side effects limit the clinical application of drugs. For recombinant uricase drugs, due to the single target and high toxic side effects, satisfactory results may not be achieved in many clinical practices. Therefore, finding an effective treatment and prevention drug for hyperuricemia nephropathy and renal fibrosis has become a hot topic of research at home and abroad.

[0004] Chinese patent CN 116870068 A discloses the use of a Xanthoceras sorbifolia leaf extract in the preparation of a drug or health product for preventing or treating hyperuricemia nephropathy; the hyperuricemia nephropathy includes tubulointerstitial fibrosis, glomerular hyperfiltration or renal hypertrophy, and early glomerular sclerosis. Chinese patent CN 109394753A relates to the use of dioscorea lignin in the preparation of a drug for preventing and / or treating hyperuricemia nephropathy. Dioscorea lignin alone or in combination with allopurinol can significantly reduce serum urea nitrogen and creatinine levels while reducing serum uric acid in hyperuricemia nephropathy mice, and can also reduce the increase in mouse renal index caused by hyperuricemia, and the spleen index is also significantly increased, indicating that the combination of the two drugs can reverse the damage to the mouse renal function caused by increased serum uric acid while reducing uric acid in hyperuricemia nephropathy mice, thereby protecting the renal function of hyperuricemia mice and having a protective effect on their immune system.

[0005] Ligustilide (LIG) is a phthalide derivative derived from natural medicines such as Chinese herbal medicines Angelica sinensis and Chuanxiong. It has been reported to have pharmacological effects such as anti-apoptosis, anti-inflammatory, and antioxidant, especially for the kidneys. However, due to the instability of the structure of ligustilide and poor drugability, LIG ​​was modified to synthesize a more stable structural modification, which was modified to ligusticum cycloprolactam (LIGc). The compound is a white crystalline powder, slightly soluble in water, and easily soluble in organic solvents such as methanol, ethanol, acetone, and ethyl acetate. The molecular formula of ligustilide is C 15 H 21 NO2, molecular weight is 247, and the molecular structure is as follows:

[0006]

[0007] At present, there are no reports on the application of cyclopropane in hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia. Summary of the invention

[0008] In view of the above problems, the present invention provides an application of Ligusticum chuanxiong cyclopropane lactone in the preparation of drugs for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia. In the present invention, Ligusticum chuanxiong cyclopropane lactone, as a natural medicinal plant source material, has lower toxic and side effects and multi-target effects, and has good clinical application prospects.

[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0010] On the one hand, the present invention provides an application of Ligusticum chuanxiong cyclopropane lactam in the preparation of a drug for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis induced by hyperuricemia.

[0011] Preferably, the Ligusticum chuanxiong cyclopropane lactam is the main active ingredient in the drug for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia.

[0012] Preferably, the drug comprises pharmaceutically acceptable excipients.

[0013] Preferably, the auxiliary material includes at least one of a diluent, an excipient, a filler, an emulsifier, a binder, a lubricant, a pH adjuster, a flavoring agent, a surfactant, a disintegrant or an antioxidant.

[0014] Preferably, the auxiliary materials include but are not limited to starch, pregelatinized starch, dextrin, sucrose, lactose, mannitol, sorbitol, microcrystalline cellulose, sodium pyrosulfite, sodium bisulfite, sodium thiosulfate, cysteine ​​hydrochloride, thioglycolic acid, soybean lecithin, vitamin C, vitamin E, disodium EDTA, sodium calcium EDTA, carbonate, acetate, phosphate of monovalent alkali metal or its aqueous solution, hydrochloric acid, acetic acid, sulfuric acid, phosphoric acid, amino acid, sodium chloride, potassium chloride, sodium lactate, ethyl hydroxybenzoate, benzoic acid, potassium sorbate, chlorhexidine acetate, xylitol, maltose, glucose, fructose, dextran, starch, sucrose, lactose, mannitol, silicon derivatives, cellulose and its derivatives, alginate, gelatin, polyvinyl pyrrolidone, glycerol, Tween 80, agar, calcium carbonate, calcium bicarbonate, surfactant, polyethylene glycol, cyclodextrin, phospholipid material, kaolin, talc, calcium stearate or magnesium stearate.

[0015] Preferably, the dosage form of the drug includes tablets, capsules, granules, pastes, powders, injections, sprays or pills.

[0016] Preferably, the tablets include but are not limited to enteric-coated tablets, coated tablets, film-coated tablets, sugar-coated tablets, dispersible tablets, sucking tablets, chewable tablets, effervescent tablets, scratched tablets, sustained-release and controlled-release dosage forms, sustained-release tablets, sustained-release coated tablets, lozenges, and oral patches.

[0017] Preferably, the capsules include but are not limited to hard capsules, soft capsules, enteric-coated capsules, sustained-release capsules, and controlled-release capsules.

[0018] Preferably, the granules include but are not limited to enteric-coated granules, sustained-release granules, fine granules, tea, suspension granules, and effervescent granules.

[0019] Preferably, the Ligusticum chuanxiong cyclopropane lactam has the effect of lowering the uric acid level in hyperuricemia nephropathy.

[0020] Preferably, the Ligusticum chuanxiong cyclopropane lactam has the effect of improving the renal function of hyperuricemia nephropathy.

[0021] Preferably, the Ligusticum chuanxiong cyclopropane lactam has the effect of improving kidney damage caused by hyperuricemia.

[0022] Preferably, the Ligusticum chuanxiong cyclopropane lactam has the effect of inhibiting inflammation caused by hyperuricemia.

[0023] Preferably, the Ligusticum chuanxiong cyclopropane lactam has the effect of improving renal fibrosis caused by hyperuricemia.

[0024] Preferably, the Ligusticum chuanxiong cyclopropane lactam has the function of regulating the expression of renal transporters in hyperuricemia nephropathy.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention provides the use of ligustifolia cyclopropane lactam in the preparation of drugs for preventing and treating hyperuricemia nephropathy and renal injury and renal fibrosis caused by hyperuricemia. The present invention constructs a mouse hyperuricemia nephropathy model, and detects and observes the mouse renal function, renal tissue pathological structure, inflammatory response and fibrosis degree through biochemical index detection, pathological staining and molecular biological methods. It is proved that ligustifolia cyclopropane lactam can improve renal injury caused by high uric acid state in mice and inhibit the process of renal fibrosis. It has small side effects and high safety, and has obvious preventive and therapeutic effects on hyperuricemia nephropathy and renal injury and renal fibrosis caused by hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the effect of Ligusticum chuanxiong cyclopropane lactam on the blood uric acid level of hyperuricemia nephropathy mice. A is the serum uric acid level (SUA) of each group of mice; B is the xanthine oxidase activity (XOD) of the liver of each group of mice.

[0028] Figure 2 The figure shows the effect of Ligusticum chuanxiong cyclopropane lactam on the renal filtration function of mice with hyperuricemia nephropathy. A is the serum creatinine level (SCr) of mice in each group; B is the serum urea nitrogen level (BUN) of mice in each group; C is the 24h urine protein (Albuminuria) of mice in each group; D is the urine creatinine level (UCr) of mice in each group.

[0029] Figure 3 The HE staining sections of the tissues in the effect of Ligusticum chuanxiong cyclopropane lactam on the renal tissue morphology of mice with hyperuricemia nephropathy. A is the HE staining of the kidneys of mice in each group; B is the statistics of the kidney injury scores of mice in each group; C is the mRNA level of KIM1 in the kidney samples of mice in each group.

[0030] Figure 4The CD68 immunohistochemical staining sections of the tissues are shown in Figure 1. The CD68 immunohistochemical staining sections of the tissues are shown in Figure 2. The CD68 immunohistochemical staining sections of the tissues are shown in Figure 3. The CD68 immunohistochemical staining sections of the tissues are shown in Figure 4.

[0031] Figure 5 The figure shows the effect of ligusticum cyclopropane lactam on the mRNA and protein expression levels of inflammatory infiltrating factors in mice with hyperuricemia nephropathy. A is the mRNA expression level of F4 / 80 in the kidney tissue of each group of mice; B is the mRNA expression level of ICAM-1 in the kidney tissue of each group of mice; C is the mRNA expression level of IL-6 in the kidney tissue of each group of mice; D is the mRNA expression level of CCL2 in the kidney tissue of each group of mice; E is the mRNA expression level of NLRP3 in the kidney tissue of each group of mice; F is the mRNA expression level of IL-1B in the kidney tissue of each group of mice.

[0032] Figure 6 The following are the sections of Masson staining and FN immunohistochemical staining of the kidney tissues of mice with hyperuricemia nephropathy. A is the Masson staining results of the kidneys of mice in each group; B is the FN immunohistochemical staining of the kidney tissues of mice in each group.

[0033] Figure 7 The figure shows the effect of ligustifolia cyclopropane lactam on the mRNA expression level of renal fibrosis factors in mice with hyperuricemia nephropathy. A is the mRNA expression level of FN in the renal tissue of each group of mice; B is the mRNA expression level of Col4a1 in the renal tissue of each group of mice; C is the mRNA expression level of TGF-β1 in the renal tissue of each group of mice; D is the mRNA expression level of Timp1 in the renal tissue of each group of mice.

[0034] Figure 8 The figure shows the effect of ligusticum cyclopropane lactam on the mRNA and protein expression levels of renal uric acid transporters in mice with hyperuricemia nephropathy. A is the mRNA expression level of ABCG2 in the renal tissue of each group of mice; B is the mRNA expression level of OAT3 in the renal tissue of each group of mice; C is the mRNA expression level of OCT2 in the renal tissue of each group of mice; D is the mRNA expression level of GLUT9 in the renal tissue of each group of mice. DETAILED DESCRIPTION

[0035] In order to make the technical means, creative features, purpose and effect of the present invention easy to understand, the present invention is further explained below in conjunction with specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without making creative work all belong to the protection scope of the present invention. It is worth noting that the raw materials used in the present invention are all common commercial products, and their sources are not specifically limited. The technology and scientific terms used in the embodiments have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs.

[0036] Example 1

[0037] The present invention provides an application of ligustifolia cyclopropane lactam in the preparation of a drug for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia. The structural formula of ligustifolia cyclopropane lactam is as follows:

[0038]

[0039] The present invention has no particular limitation on the source of the cyclopropane lactam in Ligusticum chuanxiong.

[0040] The following is a further verification experiment on the application of Ligusticum chuanxiong cyclopropane lactam in the preparation of drugs for the prevention and treatment of hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia.

[0041] 1. The experimental mice were randomly divided into 7 groups (n=10):

[0042] (1) Normal control group (NC, 0.5% CMC-Na);

[0043] (2) hyperuricemia nephropathy group (HN, Hx 500 mg / kg / d + PO 200 mg / kg / d);

[0044] (3) allopurinol (AP, 15 mg / kg / d);

[0045] (4) Benzbromarone (BBR, 7.5 mg / kg / d);

[0046] (5) LIGc low-dose group (LIGc-L, 20 mg / kg / d);

[0047] (6) LIGc medium-dose group (LIGc-M, 40 mg / kg / d);

[0048] (7) LIGc high-dose group (LIGc-H, 80 mg / kg / d).

[0049] The mice were given AP, BBR and LIGc treatment drugs by gavage at 9:00 am every day, Hx was gavaged at 15:00 pm, and PO was injected to construct the HN model for 21 consecutive days. The weight of the mice and the drinking water and diet were recorded every day during the modeling period. Before sampling, the mice were placed in a metabolic cage for 24 hours to collect the mouse urine. When sampling, the mice were anesthetized and the eyes were blooded. The supernatant was collected in a centrifuge (3500rpm, 15min) for subsequent experiments. The liver and kidneys of the mice were taken. The liver was divided into one lobe for pathology, the left kidney was half embedded and the other half was frozen, and the right kidney was quickly frozen in liquid nitrogen and then stored at -80℃.

[0050] 2. The pathological images of this experiment were statistically analyzed using Image J software. The experimental data were statistically analyzed using Prism GraphPad 8.0 software. P < 0.05 indicates that the difference between the groups is statistically significant.

[0051] 3. Observation results

[0052] (1) Ligusticum chuanxiong cyclopropane lactam reduces uric acid levels in Hx- and PO-induced hyperuricemic nephrotic mice

[0053] Uric acid levels are usually positively correlated with the severity of the disease. Uric acid levels are derived from the conversion of purines and their precursor hypoxanthine, and XOD plays a key limiting enzyme role in this process. In order to determine whether LIGc can improve the uric acid level in Hx- and PO-induced hyperuricemic nephropathy mice, the uric acid level in the mouse serum was detected.

[0054] The results are as follows Figure 1 A shows that LIGc significantly reduced the uric acid level in HN mice compared with the HN group mice, which was similar to the effect of positive drugs AP and BBR treatment. However, it is not clear whether LIGc inhibits the uric acid level in mice through the key restriction enzyme XOD, so the activity of XOD in the mouse liver was measured. Figure 1 As shown in B, compared with the HN group, the XOD activity of the LIGc-treated group decreased significantly, and the XOD inhibitory effect of the LIGc high-dose group was almost the same as that of the AP. The above results indicate that LIGc treatment helps to inhibit the XOD activity of hyperuricemia mice and thus reduce serum uric acid levels.

[0055] (2) Ligusticum chuanxiong cyclopropane lactam improves renal function in mice with hyperuricemia nephropathy induced by Hx and PO

[0056] In basic medical research and clinical practice, serum creatinine (SCr), blood urea nitrogen (BUN) and 24-hour urine protein are routinely used as standard and reliable indicators of glomerular filtration rate. Therefore, in order to further clarify whether LIGc can improve the renal function of Hx-PO-induced hyperuricemia nephropathy mice, the levels of serum creatinine, urine creatinine, urea nitrogen and 24-hour urine protein in mice were detected.

[0057] like Figure 2 AD, as expected, serum creatinine, urea nitrogen, 24h urine protein and urine creatinine in the HN model were significantly increased compared with the NC group. This showed that the kidneys of mice with hyperuricemia nephropathy induced by Hx and PO were significantly damaged. After LIGc treatment, serum creatinine, urea nitrogen and 24h urine protein were significantly reduced, which was consistent with the treatment effects of positive drugs AP and BBR. In addition, similar to the positive drug BBR treatment group, LIGc treatment significantly reduced urine creatinine levels. These results indicate that LIGc treatment restored the renal function of HN mice and improved renal filtration function.

[0058] (3) Ligusticum chuanxiong cyclopropane lactam improves renal damage in Hx-PO-induced hyperuricemia nephrotic mice

[0059] Histological analysis is a basic and main method for biological research and even disease diagnosis. The status of cells and tissues in organs can be used to infer the status of the entire body. In order to clarify the improvement effect of LIGc on the pathological damage of the kidneys of HN mice, HE staining was used to observe the mouse kidney sections, such as Figure 3 A, The renal tubules of mice in the NC group were neatly arranged, and there was no abnormality in the interstitium. In the HN group, tubular dilatation, epithelial cell shedding, obvious mononuclear cell infiltration, and crystal granulomas were clearly observed. After LIGc treatment, the renal cell morphology tended to be normal, tubular dilatation was reduced, and only a small amount of inflammatory cells gathered. At the same time, in order to quantify the degree of renal damage, such as Figure 3 B, The kidney injury score was found to be significantly higher in the HN group than in the NC group, while the kidney injury score was significantly reduced after LIGc treatment. The above results indicate that LIGc treatment can restore kidney pathological damage in hyperuricemia nephropathy mice.

[0060] Kidney injury molecule-1 (KIM1) is mainly expressed in renal epithelial cells and increases rapidly when the renal tubules are damaged. Therefore, KIM1 is considered a sensitive and specific biomarker for renal injury and has been approved by the FDA for the assessment of nephrotoxicity. Therefore, the transcriptional expression level of KIM-1 was detected by qRT-PCR.

[0061] like Figure 3As shown in C, compared with the NC group, the mRNA transcription expression level of KIM-1 in the HN model group increased by nearly 10 times, and after LIGc treatment, the mRNA level of KIM-1 decreased in a dose-dependent manner, and the high-dose group had the same effect as the positive drug AP group.

[0062] (4) Effects of ligustifolia cyclopropane lactam on inflammatory markers caused by hyperuricemia

[0063] In hyperuricemia nephropathy, the infiltration of inflammatory cells plays a very important role in the occurrence and development of renal damage. CD68 is a highly glycosylated glycoprotein that is highly expressed in macrophages and other mononuclear phagocytes. As a cytochemical marker, it is immunostained in histochemical analysis of inflammatory tissues. Immunohistochemical staining of CD68 is used to observe inflammatory infiltration in the kidneys, such as Figure 4 As shown in A, compared with the NC group, the HN group mice had obvious brown-brown areas in the renal tubules, indicating that there was obvious macrophage infiltration in the renal tubules of the mice, and LIGc intervention reduced CD68 expression in the tubules in a dose-dependent manner. At the same time, the brown areas in the positive drug AP and BBR groups were significantly reduced.

[0064] Urate crystals, as classic NLRP3 inflammasome activators, stimulate the assembly and activation of NLRP3 inflammasomes, produce IL-1β to mediate the occurrence of inflammatory responses, and produce inflammatory cascades. F4 / 80 is a marker for macrophages, which can indicate the increased accumulation or activation of cells in the kidneys. In the fields of biomedical research and clinical medicine, chemokine ligand 2 (CCL2) has been recognized as an important mediator for initiating innate immune responses and tissue inflammation. When CCL2 binds to its corresponding receptor, it can significantly promote the migration of monocytes and macrophages to the inflammatory area, thereby exacerbating the process of inflammatory response. ICAM-1 is a cell surface glycoprotein that is expressed at low basal levels in immune, endothelial and epithelial cells, but is upregulated under inflammatory stimulation, and can mediate the adhesion of leukocytes, leading to renal inflammation.

[0065] On the basis of CD68 immunohistochemistry, in order to further evaluate the effect of LIGc on inflammation in HN mice, qRT-PCR was used to detect the transcriptional expression levels of NLRP3, IL-1β, IL-6, and F4 / 80, CCL2, and ICAM-1. Figure 5 As shown in AF, compared with the NC group, the expression level of inflammatory factors in the HN group was significantly increased, and LIGc treatment could significantly inhibit the mRNA expression of NLRP3, IL-1β, IL-6, F4 / 80, CCL2, and ICAM-1. The above results indicate that LIGc can effectively inhibit the accumulation of macrophages in the kidney, block the assembly and activation of NLRP3 inflammasomes, and thus inhibit the occurrence of metabolic inflammation in HN mice.

[0066] (5) Ligusticum chuanxiong cyclopropane lactam improves renal fibrosis in Hx- and PO-induced hyperuricemic nephrotic mice

[0067] The main pathological manifestations of tubulointerstitial fibrosis are the progressive reduction of tubular epithelial cells and the abnormal accumulation of ECM. Myofibroblasts are the main cell synthesizers of ECM and can produce a large amount of collagen. The main components of ECM include FN and type IV collagen (Collagen IV). In addition, TGF-β1 also plays an important role in renal interstitial fibrosis. Therefore, immunohistochemistry was used to detect the expression of FN in mouse kidneys. At the same time, in order to further evaluate the degree of fibrosis in hyperuricemia nephropathy mice, qPCR technology was used to detect the expression of FN, Col4a1, and TGF-β1.

[0068] The accumulation of extracellular matrix in the tubulointerstitium is considered fibrosis in histological examination and is a pathological hallmark of progressive renal injury. Interstitial fibrosis is a key component of kidney disease progression and is usually measured by histological staining. In order to determine whether LIGc has an ameliorative effect on mouse kidney fibrosis, collagen fiber staining of mouse kidney tissue was performed using Masson. Figure 6 A. It was found that the collagen fiber deposition in the kidneys of mice in the HN group increased significantly, and the collagen fiber deposition in the kidneys of mice treated with LIGc decreased significantly. In addition, fibronectin is widely recognized as a key protein in the cell adhesion process. It plays a core role in the structural organization of the extracellular matrix and is generally regarded as an important organizing factor of the tissue matrix. Kidney damage can lead to tubular epithelial cell-mesenchymal cell transformation (EMT), during which epithelial cells lose their inherent characteristics and acquire the properties of mesenchymal cells, further leading to increased synthesis of the extracellular matrix (ECM), initiating repair functions and leading to overexpression of FN, which leads to renal fibrosis and thus tissue sclerosis and loss of function. Therefore, immunohistochemical staining was used to determine the expression of FN, as follows Figure 6 As shown in B, the brown-yellow staining area in the HN group was significantly increased compared with the NC group, while LIGc administration significantly reduced the brown-yellow area in the kidney tissue of mice.

[0069] Fibrosis describes the condition of excessive accumulation of ECM, among which type IV collagen, as the main component within the ECM basement membrane, is released into the ECM by endothelial and epithelial cells, promoting the fibrotic process in the kidney. Tissue inhibitor of metalloproteinases-1 (TIMP1), a naturally occurring glycoprotein, can inhibit the activation of matrix metalloproteinases (MMPs), thereby preventing the degradation of ECM. At the same time, transforming growth factor-β (TGF-β) is generally considered to be a central mediator of fibrotic diseases and a major regulator of the pathogenesis of renal fibrotic diseases. Therefore, the mRNA expression of renal fibrosis-related factors (Col4a1, Fn1, Timp1 and TGF-β1) was detected, and as expected, LIGc treatment significantly reduced the expression of these renal fibrosis-related factors mRNA, such as Figure 7 AD. The above experimental results show that LIGc treatment can delay the progression of renal fibrosis in HN mice.

[0070] (6) Ligusticum chuanxiong cyclopropane lactam regulates the expression of renal transporters in Hx- and PO-induced hyperuricemic nephropathy mice

[0071] The pathological mechanism of HN is directly related to the abnormal discharge and reabsorption of uric acid transporters. In renal function, the secretion and reabsorption of uric acid mainly depend on specific uric acid transporters, which mainly include uric acid reabsorption proteins and uric acid excretion proteins. These key proteins include GLUT9, URAT1, ABCG2, OAT1, OAT3 and OAT4. In particular, URAT1 and GLUT9 play a core role in the uric acid recycling mechanism of the kidney. Among them, URAT1 is located in the apical membrane of the proximal tubular epithelial cells, while GLUT9 is located in the apical and basolateral membranes of these cells, responsible for the recycling process of uric acid. ABCG2 has been identified as an efficient UA transport factor that regulates uric acid excretion in the kidney and extrarenal tissues. In the basolateral membrane of renal epithelial cells, OAT1 and OAT3 are responsible for transporting uric acid from the renal interstitium to the proximal tubular epithelial cells. To further clarify the possible involvement of LIGc in the pathological mechanism of HN, the expression of mRNA of uric acid transporter was evaluated by qRT-PCR. The mRNA expression of efflux proteins ABCG2, OAT3, and OCT2 was significantly reduced in the HN model group, and the reduction of mRNA was reversed after the administration of therapeutic drug LIGc and positive drugs AP and BBR. The mRNA expression of reabsorption protein GLUT9 was just the opposite. LIGc reversed the increase of GLUT9 mRNA expression, but there was no significant difference between AP and BBR groups. Figure 8 AD. These data suggest that LIGc reduces uric acid levels by reducing renal reabsorption and increasing renal efflux of uric acid in HN mice.

[0072] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A use of Ligusticum chuanxiong cyclopropane lactam in the preparation of drugs for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia.

2. The use according to claim 1, characterized in that: The ligustifolia cyclopropane lactam is the main active ingredient in the drug for preventing and treating hyperuricemia nephropathy and renal damage and renal fibrosis caused by hyperuricemia.

3. The use according to claim 1, characterized in that: The medicine includes pharmaceutically acceptable excipients.

4. The use according to claim 3, characterized in that: The auxiliary materials include at least one of diluents, excipients, fillers, emulsifiers, adhesives, lubricants, pH regulators, flavoring agents, surfactants, disintegrants or antioxidants.

5. The use according to claim 1, characterized in that: The dosage form of the medicine includes tablets, capsules, granules, ointments, powders, injections, sprays or pills.

6. The use according to claim 1, characterized in that: The Ligusticum chuanxiong cyclopropane lactam has the effect of reducing the uric acid level of hyperuricemia nephropathy.

7. The use according to claim 1, characterized in that: The Ligusticum chuanxiong cyclopropane lactam has the effect of improving the renal function of hyperuricemia nephropathy.

8. The use according to claim 1, characterized in that: The Ligusticum chuanxiong cyclopropane lactam has the effect of improving kidney damage caused by hyperuricemia.

9. The use according to claim 1, characterized in that: The Ligusticum chuanxiong cyclopropane lactam has the effect of inhibiting inflammation caused by hyperuricemia.

10. The use according to claim 1, characterized in that: The Ligusticum chuanxiong cyclopropane lactam has the effect of improving renal fibrosis caused by hyperuricemia.

Citation Information

Patent Citations

  • Phthalide derivative as well as preparation method and application thereof

    CN109053546A

  • Application of cyclopropyl lactam of radix ligustici sinensis in preparation of drugs for preventing and treating acute or chronic liver injuries and hepatic fibrosis

    CN109939108A

  • Hyperuricemia medicine composition and medicine for treating hyperuricemia

    CN111617071A

  • Medicine composition for hyperuricemia and medicine for treating hyperuricemia

    CN111617072A

  • Tetrahydroisoindolone compound as well as preparation method and application thereof

    CN115960031A